France· FR:67638519
ALGESAL SURACTIVE, crème
A medicinal product containing myrtécaïne + acide salicylique + diéthylamine, registered in France by PHARMA DEVELOPPEMENT.
Checked against Base de données publique des médicaments — BDPM (France) on
Informational only — not a medical device.
The record
At a glance
Base de données publique des médicaments — BDPM (France)- Active substance
- MYRTÉCAÏNE + ACIDE SALICYLIQUE + DIÉTHYLAMINE
- Manufacturer
- PHARMA DEVELOPPEMENT
- Country
- France (FR)
- ATC code
- —
- Reimbursed
- No
- Source register
- Base de données publique des médicaments — BDPM (France)
- Last checked
- September 12, 2026
Packs & prices · 2
- cip1334009341597701 tube(s) aluminium verni de 40 g
- cip1334009341600801 tube(s) aluminium verni de 100 g
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Base de données publique des médicaments — BDPM (France). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/b9efda0a-318a-44d3-9589-52f29e1e25c4 GET /v1/drugs/b9efda0a-318a-44d3-9589-52f29e1e25c4?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"cis": "67638519",
"date_amm": "1998-02-03",
"type_amm": "Procédure nationale",
"numero_ue": null,
"substance": "MYRTÉCAÏNE + ACIDE SALICYLIQUE + DIÉTHYLAMINE",
"statut_amm": "Autorisation active",
"statut_bdm": null,
"forme_pharmaceutique": "crème",
"voies_administration": "cutanée",
"etat_commercialisation": "Commercialisée",
"surveillance_renforcee": "Non"
}See everything about myrtécaïne + acide salicylique + diéthylamine.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.